Lurasidone (Latuda) Gains FDA Approval for Bipolar Depression in Kids

By |2021-11-11T17:02:48-08:00March 11th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for lurasidone (Latuda) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in children and adolescents aged 10 to 17 years. Lurasidone, a serotonin dopamine antagonist, is already approved in the [...]

Viewpoint: Treating Bipolar Disorder Like Cancer

By |2021-11-11T17:03:00-08:00March 5th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

In a fascinating note in today's Journal of the American Medical Association (JAMA), Robert M. Post of the George Washington University School of Medicine attributes stigma as one of the main factors contributing to inadequate recognition and treatment of recurrent mood disorders, including unipolar depression and bipolar disorder. "This Viewpoint describes an [...]

Top 5 Articles of February 2018

By |2021-11-11T17:03:19-08:00March 1st, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Top 5 Articles of February 2018 Updated for 2018 Dosing and Monitoring: Child and Adolescent Psychotropic Criteria For Children And Adolescents Psychotropic Drugs: Side Effects And Teratogenic Risks Recommended Clinical Monitoring Of Children And Adolescents For Psychotropic Drugs Internet Resources READ MORE A Pilot Evaluating Clinical Pharmacy Services in an [...]

Married to an Alcoholic? You, Too, Are at Risk

By |2021-11-11T17:03:32-08:00February 12th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

The increase in risk for alcohol use disorder (AUD) in a married individual following a diagnosis of alcoholism in the other spouse is "large and rapid," according to researchers writing recently in JAMA. The causes of this association remain unclear. Population-wide Swedish registries were used to identify individuals born in [...]

Vitamin and Mineral Supplements: What Clinicians Need to Know

By |2021-11-11T17:03:44-08:00February 7th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

By JoAnn E. Manson, and Shari S. Bassuk Dietary supplementation is approximately a $30 billion industry in the United States, with more than 90 000 products on the market. In recent national surveys, 52% of US adults reported use of at least 1 supplement product, and 10% reported use of at least 4 such [...]

Is Methamphetamine-Induced Psychosis Reversible?

By |2018-01-29T11:21:52-08:00January 29th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

According to an evidence-based review in the journal Current Psychiatry, the answer is a qualified "Maybe." Chronic methamphetamine use can induce pathological brain changes in the brain. Users can develop thought, mood, and behavioral disorders, including psychosis. Such effects may persist even after extended abstinence. Because cognitive deficits can affect [...]

Continuing Medical Education: Ascent to the Summit of the Pyramid

By |2018-04-18T11:40:22-07:00January 25th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

By Robin Stevenson, and Donald E. Moore Jr. Medical education is a continuum of 3 parts; undergraduate medical school education, postgraduate training, and continuing medical education (CME). CME differs from the other 2 educational components in that it has generally not been based on an explicit curriculum. Recently, CME has increasingly focused on addressing professional [...]

Eli Lilly’s EXPEDITION3 data is a costly lesson in rethinking Alzheimer’s

By |2018-01-25T14:45:07-08:00January 25th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Eli Lilly had hoped that EXPEDITION3 would prove to the world that amyloid beta was the cause of Alzheimer’s and that solanezumab could bend the curve of cognitive decline back to patients’ favor — or at least for patients with an early-stage, mild form of the disease. Instead, the landmark failure [...]

Medical marijuana: Do the benefits outweigh the risks?

By |2018-01-25T14:27:56-08:00January 25th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

By Sheila Gupta, Tiffany Phalen, and Sanjay Gupta There is a need for additional treatment options to improve symptoms, enhance the quality of life (QOL), and reduce suffering among patients who have chronic medical illness. Medical marijuana (MM) has the potential to help patients who have certain medical conditions in states where it [...]

Depression and Anxiety Seen in Those Concerned About Climate Change

By |2018-01-25T14:09:52-08:00January 25th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

NEW YORK (Thomson Reuters Foundation) - Depression and anxiety afflict Americans who are concerned with the fate of the environment, according to a study of the mental health effects of climate change. Most hard-hit are women and people with low incomes who worry about the planet's long-term health, said the [...]

Go to Top